| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.037 | 0.8 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |